129 related articles for article (PubMed ID: 26753721)
1. Renin gene rs1464816 polymorphism contributes to chronic kidney disease progression in ADPKD.
Ramanathan G; Elumalai R; Periyasamy S; Lakkakula BV
J Biomed Sci; 2016 Jan; 23():1. PubMed ID: 26753721
[TBL] [Abstract][Full Text] [Related]
2. Influence of angiotensin converting enzyme (
Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
[TBL] [Abstract][Full Text] [Related]
3. Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.
Gnanasambandan R; Elumalai R; Soundararajan P; Lakkakula BVKS
Clin Exp Nephrol; 2016 Aug; 20(4):561-568. PubMed ID: 26482465
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase gene is not a major susceptibility gene for progression of chronic kidney disease in patients with autosomal dominant polycystic kidney disease.
Ramanathan G; Elumalai R; Periyasamy S; Lakkakula BVKS
Saudi J Kidney Dis Transpl; 2017; 28(3):552-557. PubMed ID: 28540892
[TBL] [Abstract][Full Text] [Related]
5. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
Ramanathan G; Periyasamy S; Lakkakula BV
Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
[TBL] [Abstract][Full Text] [Related]
6. Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients.
Annapareddy SN; Elumalai R; Lakkakula BV; Ramanathan G; Periyasamy S
J Nephropharmacol; 2016; 5(1):13-18. PubMed ID: 28197493
[No Abstract] [Full Text] [Related]
7. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease.
Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V
Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482
[TBL] [Abstract][Full Text] [Related]
8. Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease.
Reiterová J; Merta M; Stekrová J; Cabartová Z; Cibulka R; Maixnerová D; Rysavá R; Ríhová Z; Tesar V; Motán J
Kidney Blood Press Res; 2006; 29(3):182-8. PubMed ID: 16943682
[TBL] [Abstract][Full Text] [Related]
9. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease.
Ramanathan G; Elumalai R; Periyasamy S; Lakkakula B
Iran J Kidney Dis; 2014 Jul; 8(4):265-77. PubMed ID: 25001132
[TBL] [Abstract][Full Text] [Related]
10. Association of the ACE gene polymorphism with the progression of autosomal dominant polycystic kidney disease.
Lee KB; Kim UK; Lee CC
J Korean Med Sci; 2000 Aug; 15(4):431-5. PubMed ID: 10983692
[TBL] [Abstract][Full Text] [Related]
11. Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD.
Lee KB; Kim UK
Yonsei Med J; 2003 Aug; 44(4):641-7. PubMed ID: 12950120
[TBL] [Abstract][Full Text] [Related]
12. A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease.
Zeltner R; Hilgers KF; Schmieder RE; Porst M; Schulze BD; Hartner A
Nephron Clin Pract; 2008; 108(3):c169-75. PubMed ID: 18277079
[TBL] [Abstract][Full Text] [Related]
13. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis.
Pereira TV; Nunes AC; Rudnicki M; Magistroni R; Albertazzi A; Pereira AC; Krieger JE
Nephrol Dial Transplant; 2006 Nov; 21(11):3155-63. PubMed ID: 16935894
[TBL] [Abstract][Full Text] [Related]
14. Modifier effect of the Glu298Asp polymorphism of endothelial nitric oxide synthase gene in autosomal-dominant polycystic kidney disease.
Stefanakis N; Ziroyiannis P; Trygonis S; Lamnissou K
Nephron Clin Pract; 2008; 110(2):c101-6. PubMed ID: 18815450
[TBL] [Abstract][Full Text] [Related]
15. [Genotype-phenotype correlation in ADPKD: a possible role for NGAL?].
Virzì GM; Gastaldon F; Corradi V; de Cal M; Cruz DN; Clementi M; Ronco C
G Ital Nefrol; 2013; 30(4):. PubMed ID: 24941494
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor polymorphism and autosomal dominant polycystic kidney disease.
Magistroni R; Manfredini P; Furci L; Ligabue G; Martino C; Leonelli M; Scapoli C; Albertazzi A
J Nephrol; 2003; 16(1):110-5. PubMed ID: 12653106
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease.
Martins DP; Souza MA; Baitello ME; Nogueira V; Oliveira CI; Pinhel MA; Caldas HC; Filho MA; Souza DR
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909926
[TBL] [Abstract][Full Text] [Related]
18. The Role of Angiotensin II Type 1 Receptor A1166C Polymorphism in Autosomal Dominant Polycystic Kidney Disease.
Sasidharan A; Mv B; Mani R; P S
Cureus; 2023 Jun; 15(6):e41136. PubMed ID: 37519589
[TBL] [Abstract][Full Text] [Related]
19. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
20. VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5.
Summers AM; Coupes BM; Brennan MF; Ralph SA; Short CD; Brenchley PE
Nephrol Dial Transplant; 2005 Nov; 20(11):2427-32. PubMed ID: 16046504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
